St. Jude Medical, Inc.
 (STJ)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Jan. 27, 8:23 AM
    • St. Jude Medical (STJ +0.5%) Q4 results: Revenues: $1,447M (+0.6%); R&D Expense: $177M (+1.1%); SG&A: $588M (+28.7%); Operating Income: $97M (-65.4%); Net Income: $113M (-53.9%); EPS: $0.39 (-53.6%); Non-GAAP EPS: $1.02 (-5.6%).
    • FY2015 results: Revenues: $5,541M (-1.4%); R&D Expense: $676M (-2.3%); SG&A: $1,878M (+1.2%); Operating Income: $1,030M (-10.5%); Net Income: $880M (-12.2%); EPS: $3.07 (-11.3%); Non-GAAP EPS: $3.94 (-5.5%); Quick Assets: $667M (-53.7%).
    • Q1 Guidance: GAAP EPS: $0.68 - 0.70; Non-GAAP EPS: $0.87 - 0.89.
    • 2016 Guidance: Revenues: $5.900B - 6.040B; GAAP EPS: $3.33 - 3.43; Non-GAAP EPS: $3.95 - 4.05.
    | Wed, Jan. 27, 8:23 AM
  • Wed, Jan. 27, 7:21 AM
    • St. Jude Medical (NYSE:STJ): Q4 EPS of $1.02 beats by $0.01.
    • Revenue of $1.45B (+0.7% Y/Y) misses by $20M.
    • Press Release
    | Wed, Jan. 27, 7:21 AM
  • Tue, Jan. 26, 5:30 PM
  • Wed, Jan. 13, 3:59 PM
    • With the aim of better aligning its reporting with how it manages its business, St. Jude Medical (STJ -6.6%) reshuffles the components of its five business segments. The changes will be in effect when the company issues Q1 results in late April. Reporting for Q4 and full-year 2015 will remain as is. The newly aligned segments are:
    • Heart Failure (HF): bi-ventricular pacemakers and implantable cardioverter-defibrillators (ICDs), ventricular assist devices and the CardioMEMS HF system. 2015 sales: $1.494B.
    • Atrial Fibrillation (AF): access, diagnostic, visualization and ablation products plus left atrial appendage closure products. 2015 sales: $1.124B.
    • Neuromodulation (NM): neurostimulation products including spinal cord stimulation, dorsal root stimulation, radiofrequency ablation for pain and deep brain stimulation for Parkinson's disease and other neurological disorders. 2015 sales: $475M.
    • Cardiovascular Disease (CV): heart valve replacement and repair devices, patent foramen ovale closure devices, structural heart defect devices, active vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, percutaneous heart pumps, renal denervation technology and vascular plugs. 2015 sales: $1.211B.
    • Traditional Cardiac Rhythm Management (CRM): single and dual chamber pacers, single and dual chamber ICDs. 2015 sales: $1.618B.
    | Wed, Jan. 13, 3:59 PM | 1 Comment
  • Wed, Jan. 13, 8:46 AM
    • On a preliminary basis, St. Jude Medical (NYSE:STJ) expects Q4 revenues of $1.447B (+1%). Thoratec products contributed ~$136M. CRM, Atrial Fibrillation, Cardiovascular and Neuromodulation sales were $580M, $276M, $327M and $128M, respectively. Non-GAAP EPS should be $1.01 - 1.02.
    • Final results will be released on January 27.
    | Wed, Jan. 13, 8:46 AM
  • Dec. 10, 2015, 9:43 AM
    | Dec. 10, 2015, 9:43 AM
  • Dec. 9, 2015, 10:22 AM
    • The FDA approves privately held Stimwave Technologies' Freedom-8A Spinal Cord Stimulation (SCS) System for the treatment of chronic back and leg pain. The fully programmable wireless device features a compact 0.4 cc profile and eight electrodes that are implanted in an outpatient setting through a standard needle without the need for general anesthesia or large surgical incision. Full commercial launch will commence in early 2016.
    • Related tickers: (MDT +0.4%)(STJ +0.5%)(BSX -0.4%)(NVRO)
    | Dec. 9, 2015, 10:22 AM
  • Dec. 7, 2015, 4:47 PM
    • St. Jude Medical (NYSE:STJ) declares $0.29/share quarterly dividend, in line with previous.
    • Forward yield 1.88%
    • Payable Jan. 29; for shareholders of record Dec. 31; ex-div Dec. 29.
    | Dec. 7, 2015, 4:47 PM
  • Nov. 30, 2015, 12:07 PM
    • St. Jude Medical (STJ +0.1%) launches its Proclaim Elite Spinal Cord Stimulation (SCS) System in Europe. The device is the only upgradeable and non-rechargeable SCS system from the company that delivers burst stimulation, designed to mimic the body's natural nerve firing patterns. Implanted patients are also safe to undergo MRI scans.
    | Nov. 30, 2015, 12:07 PM
  • Nov. 19, 2015, 9:12 AM
    • The FDA approves St. Jude Medical's (NYSE:STJ) Proclaim Elite Spinal Cord Stimulation (SCS) System for the treatment of chronic pain. It is the first upgradeable and recharge-free SCS system cleared in the U.S.  The device is also MRI-compatible for head and extremity scans.
    • The system features an Apple iPAD mini-based programmer that allows clinicians to program and adjust their patients' SCS therapy. Patients are able to directly assess their therapy with the company's Invisible Trial System, which is a discreet, app-based wireless neuromodulation programming system featured on an Apple iPAD touch mobile device.
    | Nov. 19, 2015, 9:12 AM
  • Oct. 21, 2015, 8:55 AM
    • St. Jude Medical (STJ -0.03%) Q3 results: Revenues: $1,339M (-2.4%), ICD: $392M (-7.1%), Pacemakers: $238M (-10.5%), Atrial Fibrillation: $271M (+7.1%), Cardiovascular: $317M (-2.2%), Neuromodulation: $121M (+13.1%); COGS: $425M (+3.2%); R&D Expense: $161M (-4.7%); SG&A: $413M (-8.8%); Operating Income: $294M (+8.9%); Net Income: $215M (-9.7%); EPS: $0.75 (-8.5%); Quick Assets: $2,535M (+75.8%).
    • Q4 Guidance: Revenues: $1.455B - 1.480B; GAAP EPS: $0.35 - 0.41; Non-GAAP EPS: $1.00 - 1.02.
    • 2015 Guidance: Revenues: $5.549B - 5.574 from $5.435B - 5.575B; GAAP EPS: $3.04 - 3.10; Non-GAAP EPS: $3.93 - 3.95 from $3.96 - 4.00.
    | Oct. 21, 2015, 8:55 AM | 1 Comment
  • Oct. 21, 2015, 7:18 AM
    • St. Jude Medical (NYSE:STJ): Q3 EPS of $0.97 in-line.
    • Revenue of $1.34B (-2.2% Y/Y) misses by $10M.
    | Oct. 21, 2015, 7:18 AM
  • Oct. 20, 2015, 5:30 PM
    | Oct. 20, 2015, 5:30 PM | 3 Comments
  • Oct. 20, 2015, 10:04 AM
    • St. Jude Medical (STJ +0.2%) reports Q3 results tomorrow before the open. Consensus view is EPS of $0.97 (0%) on revenues of $1.35B (-1.5%).
    | Oct. 20, 2015, 10:04 AM | 2 Comments
  • Oct. 12, 2015, 9:01 AM
    • St. Jude Medical's (NYSE:STJ) HeartMate 3 Left Ventricular Assist System (LVAS) is now CE Mark-approved in the EU. The device is indicated for cardiac support in patients with advanced heart failure who are waiting for a transplant, are in myocardial recovery or advanced heart failure patients who are not candidates for a transplant.
    • HeartMate 3 is the first commercially-approved centrifugal-flow LVAD (left ventricular assist device) that utilizes fully magnetically-levitated technology (Full MagLev). The magnetic forces suspend the device's rotor which reduces the stress to the blood as it passes through the pump.
    • The HeartMate 3, designed to supplement the pumping ability of the left ventricle, can pump up to 10 liters of blood per minute. The system includes a centrifugal pump that is implanted directly onto the patient's heart while the device itself is implanted above the diaphragm next to the heart and attached to the aorta. The patient wears an external controller and battery pack that powers the pump.
    • St. Jude acquired the rights the HeartMate 3 via its acquisition of Thoratec.
    | Oct. 12, 2015, 9:01 AM
  • Oct. 8, 2015, 5:52 PM
    • St. Jude Medical (NYSE:STJ) closes on its acquisition of Thoratec (NASDAQ:THOR), a deal it struck this summer for $3.4B that will add key products to St. Jude's heart failure portfolio.
    • All shares of Thoratec outstanding at the close today have been converted to the right to get $63.50 in cash, and the shares will be delisted from Nasdaq.
    • St. Jude expects the deal to be accretive to EPS in 2016. Analyst consensus for 2016 earnings per share is $4.34 on $5.87B in revenues.
    | Oct. 8, 2015, 5:52 PM
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.